Shahin, Mai I.; Abou El Ella, Dalal A.; Ismail, Nasser S. M.; Abouzid, Khaled A. M. published the artcile< Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold>, COA of Formula: C8H4ClN3O2, the main research area is arylaminoquinoxalinone arylaminoquinoxaline ureidoarylaminoquinoxaline preparation VEGFR2 inhibitor; structure arylaminoquinoxalinone arylaminoquinoxaline ureidoarylaminoquinoxaline inhibition VEGFR2 kinase; mol docking arylaminoquinoxalinone arylaminoquinoxaline ATP binding site VEGFR2; calculated lipophilicity solubility absorption CYP 2D6 inhibition arylaminoquinoxalinone arylaminoquinoxaline; Docking study; Kinase; Quinoxaline; Type-II; VEGFR-2.
Arylaminoquinoxalinones I [R = HO; R1 = 4-MeOC6H4NH; R2 = R3NHC(:X)NH, 4-R4C6H4SO2NH, 2-HO2CC6H4CONH, MeCONH; R3 = Ph, 3-ClC6H4, 3-MeC6H4, cyclohexyl; R4 = H, Me; X = O, S], arylaminoquinoxalines I [R = H; R1 = 4-R5C6H4NH; R2 = R3NHC(:X)NH, 4-R4C6H4SO2NH, MeCONH; R3 = Ph, 3-MeC6H4, cyclohexyl; R4 = H, Me; R5 = MeO, Cl; X = O, S] and ureidoarylaminoquinoxalines I [R = H; R1 = 4-(3-R6C6H4NHCONH)C6H4NH; R2 = O2N; R6 = H, Cl] were prepared as ATP-competitive VEGFR-2 inhibitors for potential use as antitumor agents. I (R = HO; R1 = 4-MeOC6H4; R2 = PhNHCONH) was the most effective VEGFR-2 inhibitor of the compounds prepared at a concentration of 10 μM. Mol. docking calculations were performed to rationalize the selectivities of quinoxalines for VEGFR-2; calculated physicochem. properties, absorption, and probabilities of CYP 2D6 inhibition were determined for the compounds
Bioorganic Chemistry published new progress about Biological permeation. 6272-25-9 belongs to class quinoxaline, and the molecular formula is C8H4ClN3O2, COA of Formula: C8H4ClN3O2.
Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider